Researchers are exploring a potential treatment for Alzheimer's patients, focusing on a copper-based experimental drug. This compound, known as Cu(ATSM), has shown promise due to its anti-inflammatory and neuroprotective properties. Further development of Cu(ATSM) is underway, with the drug having already progressed to the clinical trial phase for certain conditions.

More information on this experimental drug and its potential applications can be found in La Opinión.